Soluble HLA-associated peptide from PSF1 has a cancer vaccine potency

Partner of sld five 1 (PSF1) is an evolutionary conserved DNA replication factor involved in DNA replication in lower species, which is strongly expressed in normal stem cell populations and progenitor cell populations. Recently, we have investigated PSF1 functions in cancer cells and found that PSF...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 7; no. 1; pp. 11137 - 10
Main Authors Yoshida, Mari, Ishioka, Yukichi, Ozawa, Takamasa, Okuyama, Hirohisa, Iguchi, Motofumi, Ota, Takeshi, Ito, Takaomi, Nagira, Morio, Morita, Atsushi, Tanaka, Hidekazu, Naito, Hisamichi, Kidoya, Hiroyasu, Takakura, Nobuyuki
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 11.09.2017
Nature Publishing Group
Subjects
13
13/109
631/67/580/1884/2323
631/67/71
82
82/58
Cancer
Cancer vaccines
Cytotoxicity
Deoxyribonucleic acid
DNA
DNA biosynthesis
Epitopes
Evolutionary conservation
Histocompatibility antigen HLA
Humanities and Social Sciences
Immunogenicity
Immunotherapy
Interferon
Lymphocytes
Lymphocytes T
Mass spectrometry
Mass spectroscopy
multidisciplinary
Peptides
Progenitor cells
Replication
Science
Science (multidisciplinary)
Stem cells
Tumors
Vaccination
Vaccines
Online AccessGet full text

Cover

Abstract Partner of sld five 1 (PSF1) is an evolutionary conserved DNA replication factor involved in DNA replication in lower species, which is strongly expressed in normal stem cell populations and progenitor cell populations. Recently, we have investigated PSF1 functions in cancer cells and found that PSF1 plays a significant role in tumour growth. These findings provide initial evidence for the potential of PSF1 as a therapeutic target. Here, we reveal that PSF1 contains an immunogenic epitope suitable for an antitumour vaccine. We analysed PSF1 peptides eluted from affinity-purified human leukocyte antigen (HLA) by mass spectrometry and identified PSF1 79–87 peptide (YLYDRLLRI) that has the highest prediction score using an in silico algorithm. PSF1 79–87 peptide induced PSF1-specific cytotoxic T lymphocyte responses such as the production of interferon-γ and cytotoxicity. Because PSF1 is expressed in cancer cell populations and highly expressed in cancer stem cell populations, these data suggest that vaccination with PSF1 79–87 peptide may be a novel therapeutic strategy for cancer treatment.
AbstractList Partner of sld five 1 (PSF1) is an evolutionary conserved DNA replication factor involved in DNA replication in lower species, which is strongly expressed in normal stem cell populations and progenitor cell populations. Recently, we have investigated PSF1 functions in cancer cells and found that PSF1 plays a significant role in tumour growth. These findings provide initial evidence for the potential of PSF1 as a therapeutic target. Here, we reveal that PSF1 contains an immunogenic epitope suitable for an antitumour vaccine. We analysed PSF1 peptides eluted from affinity-purified human leukocyte antigen (HLA) by mass spectrometry and identified PSF1 79–87 peptide (YLYDRLLRI) that has the highest prediction score using an in silico algorithm. PSF1 79–87 peptide induced PSF1-specific cytotoxic T lymphocyte responses such as the production of interferon-γ and cytotoxicity. Because PSF1 is expressed in cancer cell populations and highly expressed in cancer stem cell populations, these data suggest that vaccination with PSF1 79–87 peptide may be a novel therapeutic strategy for cancer treatment.
Partner of sld five 1 (PSF1) is an evolutionary conserved DNA replication factor involved in DNA replication in lower species, which is strongly expressed in normal stem cell populations and progenitor cell populations. Recently, we have investigated PSF1 functions in cancer cells and found that PSF1 plays a significant role in tumour growth. These findings provide initial evidence for the potential of PSF1 as a therapeutic target. Here, we reveal that PSF1 contains an immunogenic epitope suitable for an antitumour vaccine. We analysed PSF1 peptides eluted from affinity-purified human leukocyte antigen (HLA) by mass spectrometry and identified PSF179–87 peptide (YLYDRLLRI) that has the highest prediction score using an in silico algorithm. PSF179–87 peptide induced PSF1-specific cytotoxic T lymphocyte responses such as the production of interferon-γ and cytotoxicity. Because PSF1 is expressed in cancer cell populations and highly expressed in cancer stem cell populations, these data suggest that vaccination with PSF179–87 peptide may be a novel therapeutic strategy for cancer treatment.
Partner of sld five 1 (PSF1) is an evolutionary conserved DNA replication factor involved in DNA replication in lower species, which is strongly expressed in normal stem cell populations and progenitor cell populations. Recently, we have investigated PSF1 functions in cancer cells and found that PSF1 plays a significant role in tumour growth. These findings provide initial evidence for the potential of PSF1 as a therapeutic target. Here, we reveal that PSF1 contains an immunogenic epitope suitable for an antitumour vaccine. We analysed PSF1 peptides eluted from affinity-purified human leukocyte antigen (HLA) by mass spectrometry and identified PSF179-87 peptide (YLYDRLLRI) that has the highest prediction score using an in silico algorithm. PSF179-87 peptide induced PSF1-specific cytotoxic T lymphocyte responses such as the production of interferon-γ and cytotoxicity. Because PSF1 is expressed in cancer cell populations and highly expressed in cancer stem cell populations, these data suggest that vaccination with PSF179-87 peptide may be a novel therapeutic strategy for cancer treatment.Partner of sld five 1 (PSF1) is an evolutionary conserved DNA replication factor involved in DNA replication in lower species, which is strongly expressed in normal stem cell populations and progenitor cell populations. Recently, we have investigated PSF1 functions in cancer cells and found that PSF1 plays a significant role in tumour growth. These findings provide initial evidence for the potential of PSF1 as a therapeutic target. Here, we reveal that PSF1 contains an immunogenic epitope suitable for an antitumour vaccine. We analysed PSF1 peptides eluted from affinity-purified human leukocyte antigen (HLA) by mass spectrometry and identified PSF179-87 peptide (YLYDRLLRI) that has the highest prediction score using an in silico algorithm. PSF179-87 peptide induced PSF1-specific cytotoxic T lymphocyte responses such as the production of interferon-γ and cytotoxicity. Because PSF1 is expressed in cancer cell populations and highly expressed in cancer stem cell populations, these data suggest that vaccination with PSF179-87 peptide may be a novel therapeutic strategy for cancer treatment.
Partner of sld five 1 (PSF1) is an evolutionary conserved DNA replication factor involved in DNA replication in lower species, which is strongly expressed in normal stem cell populations and progenitor cell populations. Recently, we have investigated PSF1 functions in cancer cells and found that PSF1 plays a significant role in tumour growth. These findings provide initial evidence for the potential of PSF1 as a therapeutic target. Here, we reveal that PSF1 contains an immunogenic epitope suitable for an antitumour vaccine. We analysed PSF1 peptides eluted from affinity-purified human leukocyte antigen (HLA) by mass spectrometry and identified PSF1 peptide (YLYDRLLRI) that has the highest prediction score using an in silico algorithm. PSF1 peptide induced PSF1-specific cytotoxic T lymphocyte responses such as the production of interferon-γ and cytotoxicity. Because PSF1 is expressed in cancer cell populations and highly expressed in cancer stem cell populations, these data suggest that vaccination with PSF1 peptide may be a novel therapeutic strategy for cancer treatment.
ArticleNumber 11137
Author Okuyama, Hirohisa
Ota, Takeshi
Morita, Atsushi
Ozawa, Takamasa
Tanaka, Hidekazu
Takakura, Nobuyuki
Iguchi, Motofumi
Kidoya, Hiroyasu
Nagira, Morio
Naito, Hisamichi
Yoshida, Mari
Ishioka, Yukichi
Ito, Takaomi
Author_xml – sequence: 1
  givenname: Mari
  surname: Yoshida
  fullname: Yoshida, Mari
  organization: Biomarker R&D Department, Shionogi & Co., Ltd, Department of Signal Transduction, Research Institute for Microbial Diseases, Osaka University
– sequence: 2
  givenname: Yukichi
  surname: Ishioka
  fullname: Ishioka, Yukichi
  organization: Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd
– sequence: 3
  givenname: Takamasa
  surname: Ozawa
  fullname: Ozawa, Takamasa
  organization: Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd
– sequence: 4
  givenname: Hirohisa
  surname: Okuyama
  fullname: Okuyama, Hirohisa
  organization: Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd
– sequence: 5
  givenname: Motofumi
  surname: Iguchi
  fullname: Iguchi, Motofumi
  organization: Medical Affairs Department, Shionogi & Co., Ltd
– sequence: 6
  givenname: Takeshi
  surname: Ota
  fullname: Ota, Takeshi
  organization: Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd
– sequence: 7
  givenname: Takaomi
  surname: Ito
  fullname: Ito, Takaomi
  organization: Shionogi TechnoAdvance Research Co., Ltd
– sequence: 8
  givenname: Morio
  surname: Nagira
  fullname: Nagira, Morio
  organization: Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd
– sequence: 9
  givenname: Atsushi
  surname: Morita
  fullname: Morita, Atsushi
  organization: Biomarker R&D Department, Shionogi & Co., Ltd
– sequence: 10
  givenname: Hidekazu
  surname: Tanaka
  fullname: Tanaka, Hidekazu
  organization: Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd
– sequence: 11
  givenname: Hisamichi
  surname: Naito
  fullname: Naito, Hisamichi
  organization: Department of Signal Transduction, Research Institute for Microbial Diseases, Osaka University
– sequence: 12
  givenname: Hiroyasu
  surname: Kidoya
  fullname: Kidoya, Hiroyasu
  organization: Department of Signal Transduction, Research Institute for Microbial Diseases, Osaka University
– sequence: 13
  givenname: Nobuyuki
  surname: Takakura
  fullname: Takakura, Nobuyuki
  email: ntakaku@biken.osaka-u.ac.jp
  organization: Department of Signal Transduction, Research Institute for Microbial Diseases, Osaka University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28894200$$D View this record in MEDLINE/PubMed
BookMark eNp9kV9r2zAUxcVIWdKuX2APQ7CXvbjTH8uWXgYltE0hsEK7ZyHL162KI3mSHei3r7qkJStsetEF_c7hXJ1jNPPBA0KfKTmjhMvvqaRCyYLQuqC0IqJgH9CCkTIPnLHZwTxHpyk9knwEUyVVH9GcSalKRsgCXdyGfmp6wKv1eWFSCtaZEVo8wDC6FnAXwwbf3F5S_GASNtgabyHirbHWecBDGMHbp0_oqDN9gtP9fYJ-XV7cLVfF-ufV9fJ8XdiKq7FgXSlrpiSBtu6aWplOcUlrDtCSxkpRqdZQIoWxNa0E4yWUUHUd5ZkzvFH8BP3Y-Q5Ts4HWgh-j6fUQ3cbEJx2M03-_ePeg78NWC6G44iIbfNsbxPB7gjTqjUsW-t54CFPSNAdihNVEZvTrO_QxTNHn9TIluJJc1CRTXw4TvUV5_eEMyB1gY0gpQqetG83owktA12tK9Eufetenzn3qP31qlqXsnfTV_b8ivhOlDPt7iAex_616BidzsH8
CitedBy_id crossref_primary_10_1111_imm_12936
crossref_primary_10_1097_MD_0000000000031811
crossref_primary_10_3389_fmolb_2018_00026
crossref_primary_10_1111_cas_14452
crossref_primary_10_1186_s41065_022_00258_5
crossref_primary_10_1002_mco2_210
crossref_primary_10_1016_j_lfs_2018_08_023
crossref_primary_10_3390_cancers12061660
crossref_primary_10_1002_jcp_31237
crossref_primary_10_3389_fcell_2022_951363
Cites_doi 10.1016/j.drup.2010.07.001
10.1158/0008-5472.CAN-07-6441
10.1182/blood-2008-01-136879
10.1158/0008-5472.CAN-06-2048
10.1016/j.celrep.2014.06.052
10.1038/srep03571
10.1021/pr700761w
10.1371/journal.pcbi.1003266
10.1128/MCB.25.23.10528-10532.2005
10.1110/ps.0239403
10.1158/0008-5472.CAN-08-2023
10.1007/s002510050595
10.1016/j.drup.2010.08.001
10.1016/S0090-4295(97)00480-9
10.1002/stem.102
10.1158/1078-0432.CCR-05-2267
10.1016/j.vaccine.2009.09.126
10.1146/annurev.immunol.021908.132544
10.1016/S1672-0229(06)60028-4
10.1038/nature14001
10.1084/jem.185.12.2043
10.1200/JCO.2003.08.023
10.1002/ijc.2910550212
10.1002/(SICI)1521-4141(199910)29:10<3112::AID-IMMU3112>3.0.CO;2-Q
10.1038/bmt.2013.122
10.1016/j.ab.2008.05.043
10.1002/stem.1292
10.1158/1078-0432.CCR-09-2933
10.1172/JCI69219
10.1158/0008-5472.CAN-09-3662
10.1111/j.1349-7006.2007.00603.x
10.1002/ijc.23823
10.1097/CJI.0b013e318165f5d2
10.1016/j.coi.2016.04.005
10.1007/s00262-009-0774-8
10.1158/0008-5472.CAN-07-0445
10.1158/1078-0432.CCR-07-1441
10.1186/s12935-016-0326-1
10.1002/jcp.1041290416
10.1097/CJI.0b013e31817fd90b
10.1371/journal.pone.0000594
10.1371/journal.pone.0048484
10.5114/wo.2014.47129
10.4049/jimmunol.152.1.163
10.1155/2014/860562
ContentType Journal Article
Copyright The Author(s) 2017
2017. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2017
– notice: 2017. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
NPM
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOI 10.1038/s41598-017-11605-2
DatabaseName Springer Nature OA Free Journals (Selected full-text)
CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability (subscription)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection (via ProQuest)
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
ProQuest Health & Medical Collection
Medical Database
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

CrossRef
Publicly Available Content Database
MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-2322
EndPage 10
ExternalDocumentID PMC5593935
28894200
10_1038_s41598_017_11605_2
Genre Journal Article
GroupedDBID 0R~
3V.
4.4
53G
5VS
7X7
88A
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
ABDBF
ABUWG
ACGFS
ACSMW
ACUHS
ADBBV
ADRAZ
AENEX
AEUYN
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
EJD
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
KQ8
LK8
M0L
M1P
M2P
M48
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
AFPKN
CITATION
PHGZM
PHGZT
NPM
7XB
8FK
AARCD
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
Q9U
7X8
5PM
ID FETCH-LOGICAL-c639t-2f4872980ed7fb79af938173eed0bc8569da1085ac7165234e4e6ff13f93a3b93
IEDL.DBID M48
ISSN 2045-2322
IngestDate Thu Aug 21 14:15:05 EDT 2025
Mon Jul 21 10:19:15 EDT 2025
Wed Aug 13 10:56:33 EDT 2025
Thu Apr 03 06:56:04 EDT 2025
Tue Jul 01 02:41:01 EDT 2025
Thu Apr 24 22:51:39 EDT 2025
Fri Feb 21 02:40:31 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c639t-2f4872980ed7fb79af938173eed0bc8569da1085ac7165234e4e6ff13f93a3b93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1038/s41598-017-11605-2
PMID 28894200
PQID 1953983570
PQPubID 2041939
PageCount 10
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5593935
proquest_miscellaneous_1938202708
proquest_journals_1953983570
pubmed_primary_28894200
crossref_citationtrail_10_1038_s41598_017_11605_2
crossref_primary_10_1038_s41598_017_11605_2
springer_journals_10_1038_s41598_017_11605_2
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2017-09-11
PublicationDateYYYYMMDD 2017-09-11
PublicationDate_xml – month: 09
  year: 2017
  text: 2017-09-11
  day: 11
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationTitleAlternate Sci Rep
PublicationYear 2017
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References Obama, Ura, Satoh, Nakamura, Furukawa (CR13) 2005; 14
Nagahama (CR16) 2010; 70
Lacerda, Pusztai, Woodward (CR25) 2010; 13
Hawkins (CR21) 2008; 7
Dougan, Dranoff (CR7) 2009; 27
Firat (CR36) 1999; 29
Dallas (CR10) 2009; 69
Alexander, Brady, Leffell, Tsai, Celis (CR1) 1998; 51
Johnson, Ovsyannikova, Mason, Bergen, Poland (CR39) 2009; 28
Kalbasi, June, Haas, Vapiwala (CR8) 2013; 123
Redman (CR6) 2008; 31
Chang (CR4) 2002; 8
Chang (CR5) 2003; 21
Rammensee, Bachmann, Emmerich, Bachor, Stevanović (CR19) 1999; 50
Nakahara, Tsunoda, Baba, Asabe, Tahara (CR45) 2003; 63
Wang (CR26) 2010; 13
Nielsen (CR20) 2003; 12
Calis (CR29) 2013; 9
Xu (CR32) 2009; 27
Harao (CR47) 2008; 123
CR42
Oldham (CR3) 1986; 4
Yadav (CR40) 2014; 515
Chung (CR49) 2014; 8
Enomoto (CR22) 2008; 380
Garg, Suri, Gupta, Talwar, Dubey (CR34) 2016; 16
Suda, Tsunoda, Daigo, Nakamura, Tahara (CR46) 2007; 98
CR15
LaBarge (CR24) 2010; 16
Verma (CR38) 2010; 59
Kaka, Foster, Weiss, Rooney, Leen (CR44) 2009; 31
Pellegatta (CR30) 2006; 66
Komori (CR37) 2006; 12
Ueno (CR11) 2005; 25
Zhang (CR43) 2014; 4
Pascolo (CR35) 1997; 185
Wölfel (CR2) 1993; 55
Hayashi, Arauchi, Tategu, Goto, Yoshida (CR14) 2006; 4
Bassani-Sternberg, Coukos (CR17) 2016; 41
Cho, Wang, Nie, Chen, Shin (CR23) 2008; 14
CR27
Hawkins (CR28) 2008; 7
Nakasone (CR48) 2014; 49
Garcia-Hernandez, Gray, Hubby, Klinger, Kast (CR31) 2008; 68
Nandi (CR9) 2008; 68
Comber (CR41) 2014; 2014
Ueno, Itoh, Sugihara, Asano, Takakura (CR12) 2009; 113
Duarte (CR33) 2013; 31
Parker, Bednarek, Coligan (CR18) 1994; 152
T Wölfel (11605_CR2) 1993; 55
KL Johnson (11605_CR39) 2009; 28
OE Hawkins (11605_CR28) 2008; 7
S Nakahara (11605_CR45) 2003; 63
11605_CR27
MA LaBarge (11605_CR24) 2010; 16
S Pascolo (11605_CR35) 1997; 185
M Dougan (11605_CR7) 2009; 27
H Komori (11605_CR37) 2006; 12
JD Comber (11605_CR41) 2014; 2014
Y Nagahama (11605_CR16) 2010; 70
G Zhang (11605_CR43) 2014; 4
S Nandi (11605_CR9) 2008; 68
NA Dallas (11605_CR10) 2009; 69
RK Oldham (11605_CR3) 1986; 4
M Ueno (11605_CR12) 2009; 113
K Obama (11605_CR13) 2005; 14
K Enomoto (11605_CR22) 2008; 380
R Hayashi (11605_CR14) 2006; 4
RB Alexander (11605_CR1) 1998; 51
H Firat (11605_CR36) 1999; 29
H Garg (11605_CR34) 2016; 16
QJ Xu (11605_CR32) 2009; 27
Z Wang (11605_CR26) 2010; 13
S Duarte (11605_CR33) 2013; 31
M Bassani-Sternberg (11605_CR17) 2016; 41
M Ueno (11605_CR11) 2005; 25
B Chung (11605_CR49) 2014; 8
11605_CR42
L Lacerda (11605_CR25) 2010; 13
BG Redman (11605_CR6) 2008; 31
M Nielsen (11605_CR20) 2003; 12
M Harao (11605_CR47) 2008; 123
AE Chang (11605_CR5) 2003; 21
T Suda (11605_CR46) 2007; 98
JJ Calis (11605_CR29) 2013; 9
KC Parker (11605_CR18) 1994; 152
OE Hawkins (11605_CR21) 2008; 7
S Pellegatta (11605_CR30) 2006; 66
H Nakasone (11605_CR48) 2014; 49
11605_CR15
M Yadav (11605_CR40) 2014; 515
H Rammensee (11605_CR19) 1999; 50
K Cho (11605_CR23) 2008; 14
A Kalbasi (11605_CR8) 2013; 123
MD Garcia-Hernandez (11605_CR31) 2008; 68
AS Kaka (11605_CR44) 2009; 31
B Verma (11605_CR38) 2010; 59
AE Chang (11605_CR4) 2002; 8
References_xml – volume: 13
  start-page: 109
  year: 2010
  end-page: 118
  ident: CR26
  article-title: Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance
  publication-title: Drug Resist. Updat.
  doi: 10.1016/j.drup.2010.07.001
– volume: 68
  start-page: 5778
  year: 2008
  end-page: 5784
  ident: CR9
  article-title: Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-07-6441
– volume: 113
  start-page: 555
  year: 2009
  end-page: 562
  ident: CR12
  article-title: Both alleles of PSF1 are required for maintenance of pool size of immature hematopoietic cells and acute bone marrow regeneration
  publication-title: Blood.
  doi: 10.1182/blood-2008-01-136879
– volume: 63
  start-page: 4112
  year: 2003
  end-page: 4118
  ident: CR45
  article-title: Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide
  publication-title: Cancer Res.
– volume: 66
  start-page: 10247
  year: 2006
  end-page: 10252
  ident: CR30
  article-title: Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-06-2048
– volume: 8
  start-page: 1021
  year: 2002
  end-page: 1032
  ident: CR4
  article-title: A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer
  publication-title: Clin. Cancer Res.
– volume: 152
  start-page: 163
  year: 1994
  end-page: 175
  ident: CR18
  article-title: Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains
  publication-title: J. Immunol.
– volume: 14
  start-page: 701
  year: 2005
  end-page: 706
  ident: CR13
  article-title: Up-regulation of PSF2, a member of the GINS multiprotein complex, in intrahepatic cholangiocarcinoma
  publication-title: Oncol. Rep.
– volume: 8
  start-page: 871
  year: 2014
  end-page: 882
  ident: CR49
  article-title: Antigen-specific inhibition of high avidity CTL target lysis by low avidity CTL via trogocytosis
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2014.06.052
– ident: CR42
– volume: 4
  year: 2014
  ident: CR43
  article-title: Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor
  publication-title: Sci. Rep.
  doi: 10.1038/srep03571
– volume: 7
  start-page: 1445
  year: 2008
  end-page: 1457
  ident: CR28
  article-title: Identification of Breast Cancer Peptide Epitopes Presented by HLA-A*02:01
  publication-title: J. Proteome Res.
  doi: 10.1021/pr700761w
– volume: 9
  year: 2013
  ident: CR29
  article-title: Properties of MHC class I presented peptides that enhance immunogenicity
  publication-title: PLoS Comput. Biol.
  doi: 10.1371/journal.pcbi.1003266
– volume: 25
  start-page: 10528
  year: 2005
  end-page: 10532
  ident: CR11
  article-title: PSF1 is essential for early embryogenesis in mice
  publication-title: Mol. Cell Biol.
  doi: 10.1128/MCB.25.23.10528-10532.2005
– ident: CR15
– volume: 12
  start-page: 1007
  year: 2003
  end-page: 1017
  ident: CR20
  article-title: Reliable prediction of T-cell epitopes using neural networks with novel sequence representations
  publication-title: Protein Sci.
  doi: 10.1110/ps.0239403
– volume: 69
  start-page: 1951
  year: 2009
  end-page: 1957
  ident: CR10
  article-title: Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-08-2023
– volume: 50
  start-page: 213
  year: 1999
  end-page: 219
  ident: CR19
  article-title: SYFPEITHI: database for MHC ligands and peptide motifs
  publication-title: Immunogenetics.
  doi: 10.1007/s002510050595
– volume: 2014
  year: 2014
  ident: CR41
  article-title: MHC class I presented T cell epitopes as potential antigens for therapeutic vaccine against HBV chronic infection
  publication-title: Hepat. Res. Treat.
– volume: 13
  start-page: 99
  year: 2010
  end-page: 108
  ident: CR25
  article-title: The role of tumor initiating cells in drug resistance of breast cancer: Implications for future therapeutic approaches
  publication-title: Drug Resist. Updat.
  doi: 10.1016/j.drup.2010.08.001
– volume: 51
  start-page: 150
  year: 1998
  end-page: 157
  ident: CR1
  article-title: Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer
  publication-title: Urology.
  doi: 10.1016/S0090-4295(97)00480-9
– volume: 27
  start-page: 1734
  year: 2009
  end-page: 1740
  ident: CR32
  article-title: Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens
  publication-title: Stem Cells.
  doi: 10.1002/stem.102
– volume: 12
  start-page: 2689
  year: 2006
  end-page: 2697
  ident: CR37
  article-title: Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-05-2267
– volume: 28
  start-page: 38
  year: 2009
  end-page: 47
  ident: CR39
  article-title: Discovery of naturally processed and HLA-presented class I peptides from vaccinia virus infection using mass spectrometry for vaccine development
  publication-title: Vaccine.
  doi: 10.1016/j.vaccine.2009.09.126
– volume: 27
  start-page: 83
  year: 2009
  end-page: 117
  ident: CR7
  article-title: Immune therapy for cancer
  publication-title: Annu. Rev. Immunol.
  doi: 10.1146/annurev.immunol.021908.132544
– ident: CR27
– volume: 4
  start-page: 156
  year: 2006
  end-page: 164
  ident: CR14
  article-title: A combined computational and experimental study on the structure-regulation relationships of putative mammalian DNA replication initiator GINS
  publication-title: Genomics Proteomics Bioinformatics.
  doi: 10.1016/S1672-0229(06)60028-4
– volume: 515
  start-page: 572
  year: 2014
  end-page: 576
  ident: CR40
  article-title: Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
  publication-title: Nature.
  doi: 10.1038/nature14001
– volume: 185
  start-page: 2043
  year: 1997
  end-page: 2051
  ident: CR35
  article-title: HLA-A2.1-restricted education and cytolytic activity of CD8 T lymphocytes from b2 microglobulin (b2m) HLA-A2.1 monochain transgenic H-2Db b2m double knockout mice
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.185.12.2043
– volume: 21
  start-page: 884
  year: 2003
  end-page: 890
  ident: CR5
  article-title: Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2003.08.023
– volume: 55
  start-page: 237
  year: 1993
  end-page: 244
  ident: CR2
  article-title: Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL)
  publication-title: Int. J. Cancer.
  doi: 10.1002/ijc.2910550212
– volume: 7
  start-page: 1445
  year: 2008
  end-page: 1457
  ident: CR21
  article-title: Identification of Breast Cancer Peptide Epitopes Presented by HLA-A*02:01
  publication-title: J. Proteome Res.
  doi: 10.1021/pr700761w
– volume: 29
  start-page: 3112
  year: 1999
  end-page: 3121
  ident: CR36
  article-title: H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies
  publication-title: Eur. J. Immunol.
  doi: 10.1002/(SICI)1521-4141(199910)29:10<3112::AID-IMMU3112>3.0.CO;2-Q
– volume: 49
  start-page: 87
  year: 2014
  end-page: 94
  ident: CR48
  article-title: Single-cell T-cell receptor-β analysis of HLA-A*2402-restricted CMV- pp65-specific cytotoxic T-cells in allogeneic hematopoietic SCT
  publication-title: Bone Marrow Transplant.
  doi: 10.1038/bmt.2013.122
– volume: 380
  start-page: 249
  year: 2008
  end-page: 256
  ident: CR22
  article-title: A double epitope tag for quantification of recombinant protein using fluorescence resonance energy transfer
  publication-title: Anal. Biochem.
  doi: 10.1016/j.ab.2008.05.043
– volume: 31
  start-page: 423
  year: 2013
  end-page: 432
  ident: CR33
  article-title: Preventive cancer stem cell-based vaccination reduces liver metastasis development in a rat colon carcinoma syngeneic model
  publication-title: Stem Cells.
  doi: 10.1002/stem.1292
– volume: 16
  start-page: 3121
  year: 2010
  end-page: 3129
  ident: CR24
  article-title: The difficulty of targeting cancer stem cell niches
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-09-2933
– volume: 123
  start-page: 2756
  year: 2013
  end-page: 2763
  ident: CR8
  article-title: Radiation and immunotherapy: a synergistic combination
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI69219
– volume: 70
  start-page: 1215
  year: 2010
  end-page: 1224
  ident: CR16
  article-title: PSF1, a DNA replication factor expressed widely in stem and progenitor cells, drives tumorigenic and metastatic properties
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-09-3662
– volume: 98
  start-page: 1803
  year: 2007
  end-page: 1808
  ident: CR46
  article-title: Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy
  publication-title: Cancer Sci.
  doi: 10.1111/j.1349-7006.2007.00603.x
– volume: 123
  start-page: 2616
  year: 2008
  end-page: 2625
  ident: CR47
  article-title: HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL
  publication-title: Int. J. Cancer.
  doi: 10.1002/ijc.23823
– volume: 31
  start-page: 359
  year: 2009
  end-page: 369
  ident: CR44
  article-title: Using dendritic cell maturation and IL-12 producing capacity as markers of function: A cautionary tle
  publication-title: J. Immunother.
  doi: 10.1097/CJI.0b013e318165f5d2
– volume: 41
  start-page: 9
  year: 2016
  end-page: 17
  ident: CR17
  article-title: Mass spectrometry-based antigen discovery for cancer immunotherapy
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2016.04.005
– volume: 59
  start-page: 563
  year: 2010
  end-page: 573
  ident: CR38
  article-title: Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-009-0774-8
– volume: 68
  start-page: 861
  year: 2008
  end-page: 869
  ident: CR31
  article-title: Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-07-0445
– volume: 14
  start-page: 1310
  year: 2008
  end-page: 1316
  ident: CR23
  article-title: Therapeutic nanoparticles for drug delivery in cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-07-1441
– volume: 16
  year: 2016
  ident: CR34
  article-title: Survivin: a unique target for tumor therapy
  publication-title: Cancer Cell Int.
  doi: 10.1186/s12935-016-0326-1
– volume: 4
  start-page: 91
  year: 1986
  end-page: 99
  ident: CR3
  article-title: Biotherapy: the fourth modality of cancer treatment
  publication-title: J. cell Physiol. Suppl.
  doi: 10.1002/jcp.1041290416
– volume: 31
  start-page: 591
  year: 2008
  end-page: 598
  ident: CR6
  article-title: Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma
  publication-title: J. Immunother.
  doi: 10.1097/CJI.0b013e31817fd90b
– volume: 31
  start-page: 591
  year: 2008
  ident: 11605_CR6
  publication-title: J. Immunother.
  doi: 10.1097/CJI.0b013e31817fd90b
– volume: 13
  start-page: 109
  year: 2010
  ident: 11605_CR26
  publication-title: Drug Resist. Updat.
  doi: 10.1016/j.drup.2010.07.001
– volume: 41
  start-page: 9
  year: 2016
  ident: 11605_CR17
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2016.04.005
– volume: 12
  start-page: 2689
  year: 2006
  ident: 11605_CR37
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-05-2267
– volume: 123
  start-page: 2756
  year: 2013
  ident: 11605_CR8
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI69219
– volume: 68
  start-page: 5778
  year: 2008
  ident: 11605_CR9
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-07-6441
– volume: 185
  start-page: 2043
  year: 1997
  ident: 11605_CR35
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.185.12.2043
– volume: 51
  start-page: 150
  year: 1998
  ident: 11605_CR1
  publication-title: Urology.
  doi: 10.1016/S0090-4295(97)00480-9
– volume: 31
  start-page: 359
  year: 2009
  ident: 11605_CR44
  publication-title: J. Immunother.
  doi: 10.1097/CJI.0b013e318165f5d2
– volume: 25
  start-page: 10528
  year: 2005
  ident: 11605_CR11
  publication-title: Mol. Cell Biol.
  doi: 10.1128/MCB.25.23.10528-10532.2005
– volume: 68
  start-page: 861
  year: 2008
  ident: 11605_CR31
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-07-0445
– volume: 380
  start-page: 249
  year: 2008
  ident: 11605_CR22
  publication-title: Anal. Biochem.
  doi: 10.1016/j.ab.2008.05.043
– volume: 515
  start-page: 572
  year: 2014
  ident: 11605_CR40
  publication-title: Nature.
  doi: 10.1038/nature14001
– volume: 123
  start-page: 2616
  year: 2008
  ident: 11605_CR47
  publication-title: Int. J. Cancer.
  doi: 10.1002/ijc.23823
– ident: 11605_CR15
  doi: 10.1371/journal.pone.0000594
– volume: 4
  year: 2014
  ident: 11605_CR43
  publication-title: Sci. Rep.
  doi: 10.1038/srep03571
– volume: 14
  start-page: 1310
  year: 2008
  ident: 11605_CR23
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-07-1441
– ident: 11605_CR42
  doi: 10.1371/journal.pone.0048484
– volume: 8
  start-page: 1021
  year: 2002
  ident: 11605_CR4
  publication-title: Clin. Cancer Res.
– volume: 12
  start-page: 1007
  year: 2003
  ident: 11605_CR20
  publication-title: Protein Sci.
  doi: 10.1110/ps.0239403
– volume: 16
  year: 2016
  ident: 11605_CR34
  publication-title: Cancer Cell Int.
  doi: 10.1186/s12935-016-0326-1
– volume: 16
  start-page: 3121
  year: 2010
  ident: 11605_CR24
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-09-2933
– volume: 63
  start-page: 4112
  year: 2003
  ident: 11605_CR45
  publication-title: Cancer Res.
– volume: 28
  start-page: 38
  year: 2009
  ident: 11605_CR39
  publication-title: Vaccine.
  doi: 10.1016/j.vaccine.2009.09.126
– volume: 59
  start-page: 563
  year: 2010
  ident: 11605_CR38
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-009-0774-8
– volume: 14
  start-page: 701
  year: 2005
  ident: 11605_CR13
  publication-title: Oncol. Rep.
– volume: 21
  start-page: 884
  year: 2003
  ident: 11605_CR5
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2003.08.023
– volume: 70
  start-page: 1215
  year: 2010
  ident: 11605_CR16
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-09-3662
– volume: 49
  start-page: 87
  year: 2014
  ident: 11605_CR48
  publication-title: Bone Marrow Transplant.
  doi: 10.1038/bmt.2013.122
– volume: 29
  start-page: 3112
  year: 1999
  ident: 11605_CR36
  publication-title: Eur. J. Immunol.
  doi: 10.1002/(SICI)1521-4141(199910)29:10<3112::AID-IMMU3112>3.0.CO;2-Q
– volume: 31
  start-page: 423
  year: 2013
  ident: 11605_CR33
  publication-title: Stem Cells.
  doi: 10.1002/stem.1292
– ident: 11605_CR27
  doi: 10.5114/wo.2014.47129
– volume: 8
  start-page: 871
  year: 2014
  ident: 11605_CR49
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2014.06.052
– volume: 27
  start-page: 83
  year: 2009
  ident: 11605_CR7
  publication-title: Annu. Rev. Immunol.
  doi: 10.1146/annurev.immunol.021908.132544
– volume: 9
  year: 2013
  ident: 11605_CR29
  publication-title: PLoS Comput. Biol.
  doi: 10.1371/journal.pcbi.1003266
– volume: 50
  start-page: 213
  year: 1999
  ident: 11605_CR19
  publication-title: Immunogenetics.
  doi: 10.1007/s002510050595
– volume: 66
  start-page: 10247
  year: 2006
  ident: 11605_CR30
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-06-2048
– volume: 7
  start-page: 1445
  year: 2008
  ident: 11605_CR28
  publication-title: J. Proteome Res.
  doi: 10.1021/pr700761w
– volume: 4
  start-page: 91
  year: 1986
  ident: 11605_CR3
  publication-title: J. cell Physiol. Suppl.
  doi: 10.1002/jcp.1041290416
– volume: 152
  start-page: 163
  year: 1994
  ident: 11605_CR18
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.152.1.163
– volume: 4
  start-page: 156
  year: 2006
  ident: 11605_CR14
  publication-title: Genomics Proteomics Bioinformatics.
  doi: 10.1016/S1672-0229(06)60028-4
– volume: 69
  start-page: 1951
  year: 2009
  ident: 11605_CR10
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-08-2023
– volume: 2014
  year: 2014
  ident: 11605_CR41
  publication-title: Hepat. Res. Treat.
  doi: 10.1155/2014/860562
– volume: 55
  start-page: 237
  year: 1993
  ident: 11605_CR2
  publication-title: Int. J. Cancer.
  doi: 10.1002/ijc.2910550212
– volume: 7
  start-page: 1445
  year: 2008
  ident: 11605_CR21
  publication-title: J. Proteome Res.
  doi: 10.1021/pr700761w
– volume: 13
  start-page: 99
  year: 2010
  ident: 11605_CR25
  publication-title: Drug Resist. Updat.
  doi: 10.1016/j.drup.2010.08.001
– volume: 27
  start-page: 1734
  year: 2009
  ident: 11605_CR32
  publication-title: Stem Cells.
  doi: 10.1002/stem.102
– volume: 113
  start-page: 555
  year: 2009
  ident: 11605_CR12
  publication-title: Blood.
  doi: 10.1182/blood-2008-01-136879
– volume: 98
  start-page: 1803
  year: 2007
  ident: 11605_CR46
  publication-title: Cancer Sci.
  doi: 10.1111/j.1349-7006.2007.00603.x
SSID ssj0000529419
Score 2.291431
Snippet Partner of sld five 1 (PSF1) is an evolutionary conserved DNA replication factor involved in DNA replication in lower species, which is strongly expressed in...
SourceID pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 11137
SubjectTerms 13
13/109
631/67/580/1884/2323
631/67/71
82
82/58
Cancer
Cancer vaccines
Cytotoxicity
Deoxyribonucleic acid
DNA
DNA biosynthesis
Epitopes
Evolutionary conservation
Histocompatibility antigen HLA
Humanities and Social Sciences
Immunogenicity
Immunotherapy
Interferon
Lymphocytes
Lymphocytes T
Mass spectrometry
Mass spectroscopy
multidisciplinary
Peptides
Progenitor cells
Replication
Science
Science (multidisciplinary)
Stem cells
Tumors
Vaccination
Vaccines
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS9xAEB_8QPCltFptrC0r-NYuZrPJZfdJRDwOERFUuLew2Q8UJHf1zoL_vTPJXvQq9TkTkp3ZnfnNzM4MwKF3MgSFnqpRKvDcWMuVrhUvbOrT4HOrbdvt83Iwus3Px8U4Btxm8VrlQie2itpNLMXIjyjdoxEulOnx9A-nqVGUXY0jNFZhnVqX0a4ux2UfY6EsVi50rJVJpTqaob2imjJUzUIgkufZsj16BzLf35X8J2Ha2qHhZ_gUASQ76ST-BVZ8swUb3UjJ5204ozhX_eDZ6OKEm8h779iUbq84z6ichF1dDwW7MzNmmCWpP7K_yD7Em2w6IQz9_BVuh2c3pyMeRyVwixBjzrOAjkemVepdGepSm6Cp9Z5EC5jWVhUD7QzVGRiL_hH6nrnP_SAEIZHOyFrLHVhrJo3_Bsy4oqY-cmj7Va7QOxPSh8JT6EM4ZwYJiAXDKhv7iNM4i4eqzWdLVXVMrpDJVcvkKkvgV__OtOui8SH1_kIOVTxRs-pV_gkc9I_xLFCCwzR-8kQ0UlEwJ1UJ7HZi6z-XKaVzVAkJlEsC7Qmoz_byk-b-ru23jU4XFTAn8Hsh-je_9d9V7H28iu-wmdE2pGkUYh_W5o9P_gfim3n9s93EL33G9ig
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature HAS Fully OA
  dbid: AAJSJ
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dS8MwED_GhuCL-G39IoJvWmyadkseh2yMISKo4FtJ04QJoxtuCv733vUL5xf4nAtN75LcXe7udwDnNhPOSfRUtZTOj7QxvlSp9GMT2MDZyChToH3edkeP0fgpfmpBWNfCFEn7BaRlcU3X2WFXC1Q0VAyGdyrnaIL7eO12CKod93an3x_fj5uXFYpdRVxVFTKBkD9MXtVC30zL7xmSX8KkhfYZbsJGZTayfrnQLWjZfBvWykaS7zswoNetdGrZ6Kbv64rjNmNzylnJLKMiEnZ3P-RsohdMM0OyfmFvyDS0Mtl8Rpbz-y48DgcP1yO_apDgGzQsln7o0N0IlQxs1nNpT2mnCHBPoN4LUiPjrso0VRdog14RepyRjWzXOS6QTotUiT1o57PcHgDTWZwSehxqfBlJ9Mm4sC629ODBs0x3PeA1wxJToYdTE4tpUkSxhUxKJifI5KRgchJ6cNHMmZfYGX9SH9dySKpztEgoyKfQSOwFHpw1w3gCKKyhczt7JRoh6QknkB7sl2JrPhdKqSK8CDzorQi0ISB07dWR_HlSoGyjq0Vlyx5c1qL_tKxf_-Lwf-RHsB7StqSeFPwY2suXV3uCVs4yPa229Qf8IPU3
  priority: 102
  providerName: Springer Nature
Title Soluble HLA-associated peptide from PSF1 has a cancer vaccine potency
URI https://link.springer.com/article/10.1038/s41598-017-11605-2
https://www.ncbi.nlm.nih.gov/pubmed/28894200
https://www.proquest.com/docview/1953983570
https://www.proquest.com/docview/1938202708
https://pubmed.ncbi.nlm.nih.gov/PMC5593935
Volume 7
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZaxsxEB5yUMhLSXqkm8Oo0Ld2m9We0kMIjrExpg2hqcFvi1YrkYBZO7YT4n-fmT1M7oc8LawktDsjab6RNN8A_DB5YK1AT1UJYd1Qae0KmQk30p7xrAm11CXb51ncH4aDUTRagybdUS3A-YuuHeWTGs7Gv--ulyc44Y-rkHFxNEcjRIFiuN5yjvDcxSV5Ey1TQhkN_tZwv-L69mXIZR0783JTYgcWQoY-xbw9NFXP8Ofza5RPzlJLE9Xbho81tmTtajDswJopPsGHKtvk8jN0aQssGxvW_9N2Va0Wk7MpXWzJDaNIE3Z-0ePsUs2ZYpoGxIzdomQRirLphOD18gsMe93_nb5bZ1FwNaKPhetb9El8KTyTJzZLpLKSWPkCNI5epkUUy1xRCILS6DqhWxqa0MTW8gDrqSCTwVfYKCaF-QZM5VFGFHMIC0Qo0HHjgbGRoV0RnucqdoA3Akt1TTFOmS7GaXnUHYi0kneK8k5Leae-Az9XbaYVwcabtQ8aPaTNWEnpJFAikkw8B76vinGa0NmHKszkhuoEgvZ5POHAbqW2VXeNvh1IHil0VYEouB-XFFeXJRU3-mMU2-zAr0b1Dz7r1b_Ye3dH-7Dl02ClHBb8ADYWsxtziKhokbVgPRklLdhstwcXA3yeds_O_-HbTtxplTsNrXIy3AP1zwyI
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3ZahRBsAgR0ZdgPCeHtqBP2mR6jp3uB5GgWTZmDYIJ7Fvb0wcRwuwmu1H2p_xGq-bSNZi3PE8NM11VXfcB8Mq7NASJnqqRMvDMWMulKiXPbezj4DOrbD3t83gwOs0-TfLJGvzqemGorLKTibWgdlNLMfI9SvcoNBeK-P3sgtPWKMqudis0GrY48suf6LLN3x1-RPq-TpLhwcmHEW-3CnCL2njBk4A2eqJk7F0RykKZoGhKXYrKIi6tzAfKGSrJNxZdCXTTMp_5QQgiRTiTljR8CUX-HVS8MTl7xaToYzqUNcuEantz4lTuzVE_Ug8bqgIh0HPgyar-u2bUXq_N_CdBW-u94QPYaA1Wtt9w2Cas-eoh3G1WWC4fwQHF1cpzz0bjfW5aWnvHZlQt4zyj9hX25etQsDMzZ4ZZ4rJL9gPJhfYtm03JZl8-htNbQeITWK-mlX8GzLi8pLl1aGvITKI3KFIfck-hFuGcGUQgOoRp284tp_UZ57rOn6dSN0jWiGRdI1knEbzp35k1UztuhN7p6KDbGzzXf_gtgpf9Y7x7lFAxlZ9eEUwqKXgUywieNmTrP5dIqTIUQREUKwTtAWiu9-qT6vtZPd8bnTxqmI7gbUf6v37rv6fYuvkUL-De6OTzWI8Pj4-24X5CLEmbMMQOrC8ur_wu2laL8nnN0Ay-3fYN-g14sDK-
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3JbtNA9KlKBeKC2GsoZZDgBKN4vMTjA0JdEqW0iiKgUm_DeBYVqXJCk4Lya3wd73mjoaK3nj2WPW_fH8AbZ2PvJXqqWkrPE20Ml3kheWpCF3qXmNxU0z4ng_FJ8uk0Pd2A320vDJVVtjKxEtR2ZihG3qd0T47mQhb2fVMWMT0YfZz_4LRBijKt7TqNmkSO3OoXum-LD4cHiOu3UTQaft0f82bDADeomZc88mivR7kMnc18keXa5zSxLkbFERZGpoPcairP1wbdCnTZEpe4gfcixnM6LmgQE4r_zYy8oh5s7g0n089dhIdyaInIm06dMJb9BWpL6mhDxSAE-hE8WteG10zc65Wa_6RrKy04egD3G_OV7db09hA2XPkI7tQLLVePYUhRtuLcsfHxLtcN5p1lc6qdsY5RMwubfhkJdqYXTDNDNHfBfiLy0Npl8xlZ8KsncHIrYHwKvXJWui1g2qYFTbFDy0MmEn1DETufOgq8CGv1IADRAkyZZoo5LdM4V1U2PZaqBrJCIKsKyCoK4F33zrye4XHj6e0WD6rh54X6S30BvO4eIydSekWXbnZJZ2JJoaRQBvCsRlv3uUjKPEGBFEC2htDuAE35Xn9Sfj-rpn2jy0ft0wG8b1F_5bf-e4vnN9_iFdxF7lHHh5OjF3AvIoqktRhiG3rLi0v3Eg2tZbHTUDSDb7fNRH8ANDc4WQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Soluble+HLA-associated+peptide+from+PSF1+has+a+cancer+vaccine+potency&rft.jtitle=Scientific+reports&rft.au=Yoshida%2C+Mari&rft.au=Ishioka%2C+Yukichi&rft.au=Ozawa%2C+Takamasa&rft.au=Okuyama%2C+Hirohisa&rft.date=2017-09-11&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2045-2322&rft.volume=7&rft_id=info:doi/10.1038%2Fs41598-017-11605-2&rft_id=info%3Apmid%2F28894200&rft.externalDocID=PMC5593935
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon